DHRM [Dehaier Medical Systems] 10-Q: FORM 10-Q x For the quarterly period ended

[FORM 10-Q x For the quarterly period ended September 30, 2011 ¨ For the transition period from Dehaier Medical Systems Limited British Virgin Islands Not Applicable (State or other jurisdiction of incorporation or organization) (I.R.S. employer identification number) Room 908, East Plaza 15 West 4th Ring North Road Haidian District, Beijing 100195 People’s Republic of China +86 (10) 5166 0080] [Party A: Beijing De-haier Technology Co. Ltd. (hereinafter referred as “Party A”) Party B: Beijing Dehaier Medical Technology Co., Ltd. (hereinafter referred as “Party B”) Party A and Party B have achieved mutual agreements on the following items: I Location 45 Yong An Road, Science Park, Changping District Beijing (102200) 1,800 Party A agrees to lease space at II Leasing] [Sales Agency Agreement 1. Contracting Parties Supplier hereinafter called “party A” IMD China Co., Ltd. Address: 1-2 Floor Building 12, No. 28 Yuhua Road, Area B. Beijing Tianzhu Airport Industrial Zone, Beijing China Agent hereinafter called “party B” Beijing DeHaier Medical Technology Co., Ltd. Address: 1223 Epoch Center 31 Zizhuyuan Road, Haidian District, Beijing, China IMD Beijing DeHaier to act] [Timesco of London Ltd Timesco House, 3 Carnival Park Carnival Close, Basildon Essex SS14 3WN, England T: +44 (0) 1268 297 700 F: +44 (0) 1268 297 800 info@timesco.com E: www.timesco.com INSTRUMENTS FOR LIFE Letter of Authorization th 10 Please treat this letter as authorization for Beijing De-Haier Medical Technology Co. Ltd to be a distributor for Timesco Laryngoscopes in] [Sales Agency Agreement Contracting Parties Supplier Agent (hereinafter called "party B"): Beijing DeHaier Medical Technology Co., Ltd. I General I. product distributor two of JMS Syringe pump & Infusion pump. Beijing DeHaier to act as JMS's 2. of According to different limits a. of p of General distributor: Party A authorizes Party B to distribute certain type or certain range] [Borrower: Beijing Dehaier Medical Technology Company Limited Lender: ICBC Beijing (Fangzhuang Branch) Purpose of Line of Credit 1. The purpose of the line of credit is to allow the Borrower to finance its working capital needs (including equipment purchases). Amount of Line of Credit 2. RMB10,000,000 Line of Credit Term 3. The line of credit shall run from June 20,] [Labor Contract Beijing Dehaier Medical Technology Company Limited Party A: Yanying Qi Party B: September 30, 2011 LABOR CONTRACT Beijing Dehaier Medical Technology Co. Ltd. (hereinafter referred to as “Party A”) and Name of Employee: Yanying Qi Identification Card No.: (hereinafter referred to as “Party B”) hereby execute this Contract in accordance with the applicable provisions of “The Labor Law] [Labor Contract Beijing Dehaier Medical Technology Company Limited Party A: Xiaoqing Wang Party B: July 8, 2011 LABOR CONTRACT Beijing Dehaier Medical Technology Co. Ltd. (hereinafter referred to as “Party A”) and Name of Employee: Xiaoqing Wang Identification Card No.: (hereinafter referred to as “Party B”) hereby execute this Contract in accordance with the applicable provisions of “The Labor Law] [I, Ping Chen, certify that: (1) I have reviewed this Form 10-Q of Dehaier Medical Systems Limited; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading] [I, Yanying (Aileen) Qi, certify that: (1) I have reviewed this Form 10-Q of Dehaier Medical Systems Limited; (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the this period report fairly presents, in all material respects, the financial condition and results of operations of Dehaier Medical Systems Limited. Ping Chen Ping Chen] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the this period report fairly presents, in all material respects, the financial condition and results of operations of Dehaier Medical Systems Limited. Yanying (Aileen) Qi Yanying (Aileen) Qi Chief Financial Officer (Principal Financial Officer)]

BORN [CHINA NEW BORUN] 6-K: China New Borun Announces Third Quarter 2011 Financial

[China New Borun Announces Third Quarter 2011 Financial Results 3Q11 Revenue Increased 50.1% Year-Over-Year 3Q11 Net Income Increased 5.0% Year-Over-Year New Projects for Grade-A Edible Alcohol, Crude Corn Oil and Liquid Carbon Dioxide Commenced Production During the Quarter Beijing, China, November 11, 2011 – China New Borun Corporation (NYSE: BORN; “Borun” or the “Company”), a leading producer and distributor of]

By | 2016-04-02T15:21:10+00:00 November 10th, 2011|Categories: BORN, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x September 30, 2011 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:November 10, 2011 -------------------------------- President and Chief Executive Officer cphi10qex321093011.htm 4 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:November 10, 2011 --------------------- (principal financial officer and principal accounting officer) cphi10qex322093011.htm 5 EX-32.2]

By | 2016-02-07T22:37:27+00:00 November 10th, 2011|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments

MPEL [Melco Crown Entertainment] 6-K: Melco Crown Entertainment Announces Third Quarter 2011 Earnings

[Melco Crown Entertainment Announces Third Quarter 2011 Earnings NEW YORK, November 10, 2011 Net revenue for the third quarter of 2011 was US$1,056.0 million, representing an increase of approximately 45% from US$727.0 million for the comparable period in 2010. The increase in net revenue from the third quarter of 2010 was primarily a result of group-wide increases in rolling chip]

By | 2016-03-07T03:38:01+00:00 November 10th, 2011|Categories: Chinese Stocks, MPEL, Webplus ver|Tags: , , , , , |0 Comments

CPHI [CHINA PHARMAS,] 10-Q: FORM 10-Q (Mark One) x September 30, 2011

[FORM 10-Q (Mark One) x September 30, 2011 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMAS, Delaware 73-1564807 (State or other jurisdiction of (IRS Employerorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China570216 +86 898-6681-1730 (China)] [CERTIFICATION I, Zhilin Li certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATION I, Frank Waung, certify that: 1. I have reviewed this report on Form 10-Q of China Pharmas,; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:November 10, 2011 -------------------------------- President and Chief Executive Officer cphi10qex321093011.htm 4 EX-32.1] [18 U.S.C. SECTION 1350, SECTION 906 OF THERBANES-OXLEY ACT OF 2002 (2) The informationntained in the Report fairly presents, inl material respects, the financialndition and results of operations of thempany.ted:November 10, 2011 --------------------- (principal financial officer and principal accounting officer) cphi10qex322093011.htm 5 EX-32.2]

By | 2016-02-07T22:38:24+00:00 November 10th, 2011|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments

EGT [Entertainment Gaming Asia] 8-K: (Original Filing)

[ENTERTAINMENT GAMING ASIA INC. Nevada 001-32161 91-1696010 (State or Other Jurisdiction of (I.R.S. Employer Identification Unit 3705, 37/F, The Centrium 60 Wyndham Street Central, Hong Kong + 852-3151-3800 Not applicable (Former name or former address, if changed since last report) o o o o]

By | 2016-03-14T00:52:42+00:00 November 10th, 2011|Categories: Chinese Stocks, EGT, SEC Original|Tags: , , , , , |0 Comments

CGA [China Green Agriculture] 8-K: (Original Filing)

[China Green Agriculture, Inc. Reports First Quarter Fiscal Year 2012 Financial Results, Provides Second Quarter Fiscal Year 2012 Guidance and Raises Fiscal Year 2012’s Full Year Guidance · Q1 FY 2012 net sales increased 34.5% to $53.1 million, net income increased 37.8% to $10.7 million with EPS of $0.40 · Company Provides the Second Quarter Fiscal Year 2012 Guidance: Revenue,] [Item 2.02. Results of Operations and Financial Condition]

By | 2016-03-19T01:00:28+00:00 November 10th, 2011|Categories: CGA, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Skip to toolbar